Video

Dr. Grignani on the Future of Treatments for Sarcoma

Author(s):

Giovanni Grignani, MD

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the future of treatments for patients with soft tissue sarcoma.

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the future of treatments for patients with soft tissue sarcoma.

According to Grignani, more research is needed to improve the patient selection for each of the available drugs.

Investigating a combination of treatments that has a manageable toxicity profile is an additional form of research, explains Grignani. Additionally, introducing a more effective immunotherapy would have a great impact on the treatment paradigm.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Related Content
FDA
January 10th 2025

GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

R. Lor Randall, MD, FACS
December 5th 2024

Preclinical Data Highlight YAP1 and KRAS as Drivers in Soft Tissue Sarcomas

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
December 29th 2022

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

2rogan – stock.adobe.com
November 12th 2024

Elraglusib Earns FDA Rare Pediatric Disease Designation for Ewing Sarcoma

Pimicotinib in Tenosynovial Giant Cell Tumor | Image Credit: © 2rogan - stock.adobe.com
November 12th 2024

Pimicotinib Meets ORR End Point in Tenosynovial Giant Cell Tumor